The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...
Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results in ...
Multi-modal Speech Transformer Decoders: When Do Multiple Modalities Improve Accuracy? Authors: Guan, Y., Trinh, V.A., Voleti, V., and Whitehill, J.
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results